Dexcom (DXCM) Q2 FY26 earnings call

Dexcom delivered a strong second quarter, driven by robust demand and strategic execution across product launches and market expansion. The company advanced its "Road to 100" initiative with compelling CONNECT trial data for type 2 non-insulin diabetes, reinforcing its commitment to broader CGM access and metabolic health, while also raising full-year financial guidance.